A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 401 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... December 21, 2023 Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish... May 5, 2026 Working Outdoors in the Sunshine May Lower Your Risk of Breast... February 18, 2021 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 Load more HOT NEWS Can Acupuncture Help Cancer Survivors with Chronic Pain? Educators Raise Money in Memory of Teacher Who Dedicated Herself to... Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab...
